| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.XPHS.2020.04.021 |
| P698 | PubMed publication ID | 32380182 |
| P2093 | author name string | Xinyuan Zhang | |
| Amitava Mitra | |||
| Jennifer Dressman | |||
| Neil Parrott | |||
| Andrew Babiskin | |||
| Poonam Delvadia | |||
| Sandra Suarez-Sharp | |||
| Vidula Kolhatkar | |||
| Xavier Jh Pepin | |||
| P2860 | cites work | Quantification of gastrointestinal liquid volumes and distribution following a 240 mL dose of water in the fasted state | Q30842213 |
| Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging | Q31015624 | ||
| Physiologically based absorption modelling to predict the impact of drug properties on pharmacokinetics of bitopertin | Q34099804 | ||
| Human in vivo regional intestinal permeability: quantitation using site-specific drug absorption data | Q35616784 | ||
| Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science | Q37790383 | ||
| PBPK models for the prediction of in vivo performance of oral dosage forms | Q38141441 | ||
| In-vitro simulation of luminal conditions for evaluation of performance of oral drug products: Choosing the appropriate test media | Q38402217 | ||
| In Silico Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation and Precipitation of Posaconazole. | Q38620124 | ||
| Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug. | Q38644848 | ||
| Defining Patient Centric Pharmaceutical Drug Product Design | Q38868966 | ||
| Predicting intestinal precipitation--a case example for a basic BCS class II drug | Q39846636 | ||
| Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK. | Q40606545 | ||
| Food Effect in Humans: Predicting the Risk Through In Vitro Dissolution and In Vivo Pharmacokinetic Models | Q40987176 | ||
| Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms | Q41714891 | ||
| Application of Absorption Modeling in Rational Design of Drug Product Under Quality-by-Design Paradigm | Q41986678 | ||
| Evaluation of the use of Classical Nucleation Theory for predicting intestinal crystalline precipitation of two weakly basic BSC class II drugs | Q44421188 | ||
| Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observations | Q44811991 | ||
| Assessing the risk of pH-dependent absorption for new molecular entities: a novel in vitro dissolution test, physicochemical analysis, and risk assessment strategy. | Q45991408 | ||
| Justification of Drug Product Dissolution Rate and Drug Substance Particle Size Specifications Based on Absorption PBPK Modeling for Lesinurad Immediate Release Tablets | Q46430657 | ||
| Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective. | Q50120162 | ||
| Evaluation of fasted and fed state simulated and human intestinal fluids as solvent system in the Ussing chambers model to explore food effects on intestinal permeability. | Q51310884 | ||
| Biorelevant media for transport experiments in the Caco-2 model to evaluate drug absorption in the fasted and the fed state and their usefulness. | Q51331942 | ||
| Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test. | Q52668360 | ||
| The Irrelevance of in vitro Dissolution in Setting Product Specifications for Drugs like Dextromethorphan that are Subject to Lysosomal Trapping | Q57476302 | ||
| Physiologically-based Pharmacokinetic (PBPK) Modeling in Regulatory Science: An Update from the US Food and Drug Administration's Office of Clinical Pharmacology | Q58598407 | ||
| Drug Transport across Porcine Intestine Using an Ussing Chamber System: Regional Differences and the Effect of P-Glycoprotein and CYP3A4 Activity on Drug Absorption | Q64067193 | ||
| Applications of Clinically Relevant Dissolution Testing: Workshop Summary Report | Q64122589 | ||
| Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model | Q84263667 | ||
| Modeling and simulation of biopharmaceutical performance | Q87712003 | ||
| The BioGIT System: a Valuable In Vitro Tool to Assess the Impact of Dose and Formulation on Early Exposure to Low Solubility Drugs After Oral Administration | Q88802883 | ||
| Food Effect Projections via Physiologically Based Pharmacokinetic Modeling: Predictive Case Studies | Q89115461 | ||
| In vitro methods to assess drug precipitation in the fasted small intestine - a PEARRL review | Q89339782 | ||
| Application of the GastroDuo as an in Vitro Dissolution Tool To Simulate the Gastric Emptying of the Postprandial Stomach | Q90589315 | ||
| In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration | Q90720164 | ||
| PBPK Absorption Modeling: Establishing the In Vitro-In Vivo Link-Industry Perspective | Q91182830 | ||
| Prediction of pH-Dependent Drug-Drug Interactions for Basic Drugs Using Physiologically Based Biopharmaceutics Modeling: Industry Case Studies | Q91510523 | ||
| Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices | Q91889907 | ||
| Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part I. Mechanistic modelling of drug product dissolution to derive a P-PSD for PBPK model input | Q91889930 | ||
| P577 | publication date | 2020-05-04 | |
| P1433 | published in | Journal of Pharmaceutical Sciences | Q3186933 |
| P1476 | title | Current State and Future Expectations of Translational Modeling Strategies to Support Drug Product Development, Manufacturing Changes and Controls: A Workshop Summary Report |
| Q101354662 | Applications of Physiologically Based Biopharmaceutics Modeling (PBBM) to support Drug Product Quality: A Workshop Summary Report |
| Q100568976 | Best Practices in the Development and Validation of Physiologically Based Biopharmaceutics Modeling. A Workshop Summary Report |
| Q99589896 | In Vitro Biopredictive Methods: A Workshop Summary Report |
Search more.